Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Feb 28:13:1164081.
doi: 10.3389/fonc.2023.1164081. eCollection 2023.

Editorial: Advances in the treatment of Hodgkin lymphoma

Matthew Mei  1 , Guilherme Perini  2 , Radhakrishnan Ramchandren  3
Affiliations
Editorial

Editorial: Advances in the treatment of Hodgkin lymphoma

Matthew Mei et al. Front Oncol. .
No abstract available

Keywords: Hodgkin lymphoma; brentuximab vedotin; chemotherapy; elderly; stem cell transplantation.

PubMed Disclaimer

Conflict of interest statement

MM declares consultancy with Novartis, SeaGen, CTI, Janssen, and EUSA; speakers’ bureau with SeaGen and Morphosys; research funding from BMS, BeiGene, and Morphosys. GP declares consultancy with Abbvie, Janssen, and Takeda. RR declares a research funding from Merck and Seagen and consultancy with Merck and Seagen.

Comment on

  • Editorial on the Research Topic Advances in the treatment of Hodgkin lymphoma

References

    1. Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, et al. . Overall survival with brentuximab vedotin in stage III or IV hodgkin’s lymphoma. New Engl J Med (2022) 387(4):310–20. doi: 10.1056/NEJMoa2206125 - DOI - PubMed
    1. Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, et al. . Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol (2021) 39(28):3109–17. doi: 10.1200/JCO.21.01056 - DOI - PMC - PubMed
    1. Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, et al. . Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood (2022) 139(25):3605–16. doi: 10.1182/blood.2022015423 - DOI - PMC - PubMed
    1. Ding K, Liu H, Ma J, Yang H, Cao L, Wang H, et al. . Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: A multicenter phase II trial. Haematologica (2023). doi: 10.3324/haematol.2022.282266 - DOI - PMC - PubMed
    1. Larsen CM, Garcia Arango M, Dasari H, Arciniegas Calle M, Adjei E, Rico Mesa J, et al. . Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985-2010. JAMA Netw Open (2023) 6(2):e2254669–e. doi: 10.1001/jamanetworkopen.2022.54669 - DOI - PMC - PubMed

Publication types

LinkOut - more resources